Graham Witcomb

A surge in sales and decline in margins is just what the doctor ordered. Find out more at Intelligent Investor.

As sales slow, it’s time to reevaluate the bull case for this ambitious biotech. Find out more at Intelligent Investor.

Integral is gaining market share but an industry-wide slowdown is weighing on growth. Find out more at Intelligent Investor.

A successful buyback is winding down but developments off some growth potential. Find out more at Intelligent Investor.

A merger between ACL and Healius threatens Sonic’s dominance, but it’s unlikely to succeed. Find out more at Intelligent Investor.

Buffett’s northern neighbour isn’t a household name yet. And that’s the opportunity. Find out more at Intelligent Investor.

With a flashy digital platform, Vitura leads an industry ripe for the picking. Find out more at Intelligent Investor.

Monash has shaken off its cultural issues and growth is all but assured. Find out more at Intelligent Investor.

Albumin is a small slice of sales now, but growing demand and high margins are a winning recipe. Find out more at Intelligent Investor.

The post-pandemic era is here, and it’s not the party this respiratory device maker had hoped for. Find out more at Intelligent Investor.